Monocyte deactivation--rationale for a new therapeutic strategy in sepsis - PubMed (original) (raw)

Review

. 1996 Oct:22 Suppl 4:S474-81.

doi: 10.1007/BF01743727.

Affiliations

• PMID: 8923092
• DOI: 10.1007/BF01743727

Review

Monocyte deactivation--rationale for a new therapeutic strategy in sepsis

H D Volk et al. Intensive Care Med. 1996 Oct.

Abstract

Inflammatory cells, in particular monocytes/macrophages, release pro-inflammatory mediators in response to several infectious and non-infectious stimuli. The excessive release of these mediators, resulting in the development of whole body inflammation, may play an important role in the pathogenesis of sepsis and septic shock. TNF-alpha, acting synergistically with cytokines such as IL-1, GM-CSF and IFN-gamma, is the key mediator in the induction process of septic shock, as shown in several experimental models. Based on this concept and on the encouraging results obtained in several experimental models, a number of clinical sepsis trials targeting the production or action of TNF-alpha or IL-1 have been performed in recent years. Unfortunately, these trials have failed to demonstrate a therapeutic benefit. One reason for this may be the lack of exact immunologic analyses during the course of septic disease. Recently, we demonstrated that there is a biphasic immunologic response in sepsis: an initial hyperinflammatory phase is followed by a hypo-inflammatory one. The latter is associated with immunodeficiency which is characterized by monocytic deactivation, which we have called "immunoparalysis". While anti-inflammatory therapy (e.g. anti-TNF antibodies, IL-1 receptor antagonist, IL-10) makes sense during the initial hyperinflammatory phase, immune stimulation by removing inhibitory factors (plasmapheresis) or the administration of monocyte activating cytokines (IFN-gamma, GM-CSF) may be more useful during "immunoparalysis".

PubMed Disclaimer

Similar articles

• Immunomodulatory therapies in sepsis.
  Kox WJ, Volk T, Kox SN, Volk HD. Kox WJ, et al. Intensive Care Med. 2000;26 Suppl 1:S124-8. doi: 10.1007/s001340051129. Intensive Care Med. 2000. PMID: 10786969 Review.
• Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.
  Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Döcke WD, et al. Nat Med. 1997 Jun;3(6):678-81. doi: 10.1038/nm0697-678. Nat Med. 1997. PMID: 9176497 Clinical Trial.
• The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment.
  Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH. Haveman JW, et al. Neth J Med. 1999 Sep;55(3):132-41. doi: 10.1016/s0300-2977(98)00156-9. Neth J Med. 1999. PMID: 10509072 Review.
• Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production.
  Weighardt H, Heidecke CD, Emmanuilidis K, Maier S, Bartels H, Siewert JR, Holzmann B. Weighardt H, et al. Surgery. 2000 Mar;127(3):309-15. doi: 10.1067/msy.2000.104118. Surgery. 2000. PMID: 10715987
• [Clinical trial to verify the value of the CD14(+) monocyte human leukocyte antigen DR as a marker in evaluating immunosuppression in patients with severe sepsis].
  Lin HY, Guo XS, Yao YM, Cheng WX, Weng ZH, Wei WT, Sheng ZY. Lin HY, et al. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Mar;15(3):135-8. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003. PMID: 12831612 Clinical Trial. Chinese.

Cited by

• Prognostic Value of Dynamic Segmented Neutrophil to Monocyte (SeMo) Ratio Changes in Patients with Moderate to Severe Traumatic Brain Injury.
  Chang L, Lin YJ, Tsai CH, Rau CS, Hsu SY, Hsieh CH. Chang L, et al. Diagnostics (Basel). 2024 Aug 22;14(16):1836. doi: 10.3390/diagnostics14161836. Diagnostics (Basel). 2024. PMID: 39202324 Free PMC article.
• Time-Dependent Variation in Immunoparalysis Biomarkers Among Patients with Sepsis and Critical Illness.
  Samuelsen A, Lehman E, Burrows P, Bonavia AS. Samuelsen A, et al. medRxiv [Preprint]. 2024 Jul 11:2024.07.11.24310285. doi: 10.1101/2024.07.11.24310285. medRxiv. 2024. PMID: 39040186 Free PMC article. Preprint.
• Deciphering the molecular and cellular atlas of immune cells in septic patients with different bacterial infections.
  Sun P, Cui M, Jing J, Kong F, Wang S, Tang L, Leng J, Chen K. Sun P, et al. J Transl Med. 2023 Nov 2;21(1):777. doi: 10.1186/s12967-023-04631-4. J Transl Med. 2023. PMID: 37919720 Free PMC article. Review.
• Monocytic HLA-DR Expression in Immune Responses of Acute Pancreatitis and COVID-19.
  Liu S, Luo W, Szatmary P, Zhang X, Lin JW, Chen L, Liu D, Sutton R, Xia Q, Jin T, Liu T, Huang W. Liu S, et al. Int J Mol Sci. 2023 Feb 7;24(4):3246. doi: 10.3390/ijms24043246. Int J Mol Sci. 2023. PMID: 36834656 Free PMC article. Review.
• Endotoxin tolerance and low activation of TLR-4/NF-κB axis in monocytes of COVID-19 patients.
  Dorneles GP, Teixeira PC, Peres A, Rodrigues Júnior LC, da Fonseca SG, Monteiro MC, Eller S, Oliveira TF, Wendland EM, Romão PRT. Dorneles GP, et al. J Mol Med (Berl). 2023 Feb;101(1-2):183-195. doi: 10.1007/s00109-023-02283-x. Epub 2023 Feb 15. J Mol Med (Berl). 2023. PMID: 36790534 Free PMC article.

References

1. 1. Lancet. 1991 Sep 21;338(8769):732-6 - PubMed
2. 1. J Infect Dis. 1991 Jan;163(1):83-8 - PubMed
3. 1. J Immunol. 1992 Mar 15;148(6):1890-7 - PubMed
4. 1. Science. 1985 Aug 30;229(4716):869-71 - PubMed
5. 1. JAMA. 1990 Feb 16;263(7):937-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information